AiTan (rivoceranib) / Jiangsu Hengrui Pharma, HLB Bio Group, Bukwang Pharma, Advenchen - LARVOL DELTA

Rechallenge of anti-PD-1 antibody combined with chemotherapy shows promising efficacy in the treatment of advanced metastatic hepatocellular carcinoma: A case report. (PubMed, Oncol Lett) - "The lung metastasis progressed multiple times while the patient was undergoing successive treatments with Lenvatinib, Apatinib combined with Camrelizumab and Regorafenib. The patient has been receiving Tislelizumab combined with Xelox for 23 months and has maintained a complete response to treatment. This case indicates that combining immune rechallenge with chemotherapy is beneficial for metastatic hepatocellular carcinoma."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial. (PubMed, BMC Med) - P4 | "Apatinib significantly improved the treatment effects of TACE for patients with unresectable HCC. TACE-apatinib could serve as a promising treatment option for this patient population, offering notable survival benefits while maintaining an acceptable safety profile."

Journal • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Nanfang Hospital, Southern Medical University | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): An open-label, single-arm, phase 2 study. (ASCO 2025) - P2 | "Patients with LA-HNSCC received two cycles of tislelizumab (200mg) and TP (nab-paclitaxel and cisplatin) chemotherapy, administrated on day one of each three-week cycle, along with afatinib (30mg) during the intermittent period between chemoimmunotherapy cycles, followed by 15 cycles of adjuvant tislelizumab treatment. This study firstly reported the promising efficacy and acceptable safety profile of neoadjuvant chemoimmunotherapy combined with apatinib in the treatment of patients with LA-HNSCC. Further evaluation in large-scale clinical trials with longer follow-up periods is needed."

Clinical • IO biomarker • Metastases • P2 data • Alopecia • Head and Neck Cancer • Immunology • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD8

CCGLC-001: Combined HAIC, TKI/anti-VEGF and ICIs As Conversion Therapy for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Ze-yang Ding, MD | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Apr 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma: A multicenter real-world study. (ASCO 2025) - "Systemic therapy regimens with the highest conversion success rates included apatinib plus toripalimab (42.9%), lenvatinib plus tislelizumab (32.4%), and apatinib plus tislelizumab (30.8%). Locoregional combined with systemic therapy is an effective strategy for conversion treatment. Conversion surgery offers substantial survival benefits, while palliative surgery may also serve as a viable therapeutic option."

Clinical • Real-world • Real-world evidence • Biliary Cancer • Cholangiocarcinoma • Oncology • Palliative care • Solid Tumor

Integrating quality of life and overall survival to quantify benefit from frontline systemic therapy options in unresectable/advanced hepatocellular carcinoma: a network meta-analysis (EASL 2025) - " Ten studies, enrolling 7,268 patients treated with Sorafenib, Lenvatinib, Nivolumab, Tislelizumab, Durvalumab, Atezolizumab+Bevacizumab, Sintilimab+IBI305, Durvalumab+Tremelimumab, Nivolumab+Ipilimumab, Atezolizumab+Cabozantinib, Lenvatinib+Pembrolizumab, Camrelizumab+Apatinib were included... Atezolizumab plus Bevacizumab was associated with the highest magnitude in reducing the risk of deterioration of most HR-QoL domains compared to other systemic therapies. Integrated assessment of OS with HR-QoL assessed by MDC suggests atezolizumab plus bevacizumab to provide the best balance between QoL preservation and OS benefit compared to other systemic therapy options in unresectable/advanced HCC."

HEOR • Metastases • Retrospective data • Fatigue • Hepatocellular Cancer • Hepatology • Oncology • Pain • Solid Tumor

Cinobufagin inhibits hepatocellular carcinoma EMT-like stemness via VEGF/VEGFR2 autocrine signaling. (PubMed, Discov Oncol) - "Cinobufagin may attenuate the PI3K/AKT-dependent metastatic potential of hepatocellular carcinoma by inhibiting the VEGFa/VEGFR2 autocrine pathway."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • Transplantation

Tumor microenvironment-responsive nanoregulator CoMnMOF superparticles for enhanced microwave dynamic therapy via multi-pronged amplification of reactive oxygen species. (PubMed, J Colloid Interface Sci) - "To address these bottlenecks, we designed a multifunctional nanoregulator CoMnMOF@Apatinib@l-menthol@RBC-HA (denoted as CMALRH) to achieve enhanced MDT via a multi-pronged ROS amplification strategy...The experiments in vitro and in vivo confirmed the enhanced MDT in combination with microwave thermal therapy can successfully inhibit the proliferation of breast cancer. This TME based ROS amplification strategy provides an avenue for the development of remarkably high efficiency MDT and MW thermal therapy."

Biomarker • Journal • Breast Cancer • Oncology • Solid Tumor

Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01). (ASCO 2025) - P1/2 | "For TPC arm, one of the standard of care (SOC) drugs (apatinib, paclitaxel, docetaxel, irinotecan or nivolumab) was given per physician's decision... This is the first confirmatory RCT of CAR T-therapy in solid tumors. Satri-cel demonstrated significant PFS improvement and an obvious OS benefit with a manageable safety profile. These results support satri-cel as a potential new SOC for advanced G/GEJC."

CAR T-Cell Therapy • Clinical • Metastases • P2 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CLDN18

Preliminary study of apatinib combined with fluzoparib in the treatment of HRP ovarian cancer via the HR pathway. (PubMed, Transl Cancer Res) - "The combination of apatinib and fluzoparib may cause changes in the HR pathway by down-regulating MEK signaling in ovarian cancer, leading to the down-regulation of RAD51. This eventually leads to the increased expression of DNA damage-related protein γH2AX, which plays a therapeutic role in ovarian cancer in vitro and in vivo."

Journal • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • Transplantation • BRCA1 • RAD51

The appropriate therapeutic sequence with angiogenesis inhibitor and chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Exploratory analysis from the phase 3 FRUTIGA study. (ASCO 2025) - P3 | "In China, approved AI-based treatments include ramucirumab (a monoclonal antibody AI targeting VEGFR-2) plus paclitaxel (PTX) for 2L therapy, and apatinib (a small-molecule AI targeting VEGFR-2) for 3L therapy... In the FRUTIGA study, eligible patients (pts) were randomized to receive fruquintinib (F, an AI targeting VEGFR-1/2/3) or placebo (PBO) + PTX for 2L therapy...The commonly used C in FP-C arm were irinotecan (70.7%) and PTX (17.2%); the most commonly used AI in PP-AI arm was apatinib (93.2%)... This analysis revealed superior survival benefits in FP-C arm vs PP-AI arm, which indicates that compared with chemotherapy followed by angiogenesis inhibitor-based therapy, the therapeutic sequence of angiogenesis inhibitor-based therapy followed by chemotherapy may be predictive of better clinical outcomes for pts with advanced gastric or gastroesophageal junction adenocarcinoma. However, this exploratory analysis warrants further study."

Clinical • Metastases • P3 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • FLT1 • KDR

Comprehensive analysis on reactive cutaneous capillary endothelial proliferation following camrelizumab-based therapy in patients with solid tumors: A large-scale pooled analysis of nine phase 2 or phase 3 registration trials. (ASCO 2025) - "Patients with advanced non-small cell lung cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, and gastric cancer treated with camrelizumab monotherapy (Camre), camrelizumab plus apatinib (Camre-Apa), or camrelizumab plus chemotherapy (Camre-Chemo) were included. Although RCCEP occurred commonly, most events were mild without impact on camrelizumab treatment. RCCEP occurred early with 1-2 events mainly in each patient. The occurrence of RCCEP was positively associated with both short-term response and long-term survival, regardless of camrelizumab monotherapy or combination therapy."

P2 data • P3 data • Retrospective data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Hepatocellular Cancer • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Camrelizumab plus chemotherapy or apatinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma: A double-cohort phase II study. (ASCO 2025) - P2 | "In Arm A, patients received camrelizumab (200 mg intravenous, day 1), followed by docetaxel (75 mg/m²) and cisplatin (75 mg/m²) or carboplatin (area under the curve 5) on day 2 every 3 weeks for up to six cycles, followed by camrelizumab monotherapy (200 mg intravenous, day 1, every 3 weeks). Camrelizumab combined with chemotherapy or apatinib demonstrated encouraging survival outcomes, with a favorable safety profile. These findings support further investigation of camrelizumab-based regimens as first-line treatments for patients with recurrent or metastatic HNSCC."

Clinical • Metastases • P2 data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Adjuvant apatinib following concurrent chemoradiotherapy in high-risk nasopharyngeal carcinoma: A multicenter, prospective, phase 2 study. (ASCO 2025) - P2 | "All patients were randomly assigned (1:1) to receive apatinib mesylate tablet for adjuvant treatment (the dose was 250 mg, orally, qd, 28 days for an observation period, six cycles) of high-risk metastasis NPC after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin) or only observation after IMRT with concurrent chemotherapy (CCRT). This phase II trial showed that adjuvant apatinib following concurrent chemoradiotherapy significantly improved survival and was well tolerated in patients with high-risk NPC. Clinical trial information: NCT 03612219."

Clinical • P2 data • Cardiovascular • Dermatology • Hematological Disorders • Hypertension • Leukopenia • Nasopharyngeal Carcinoma • Oncology • Pain • Solid Tumor

Assessing comparative efficacies of camrelizumab as a single or combination therapy in patients with hepatocellular carcinoma: A systematic review and network meta-analysis. (ASCO 2025) - "In this systematic review and network meta-analysis, we aim to compare CAM monotherapy with its combinations with other agents like Lenvatinib (LEN), Sorafenib (SOR), Rivoceranib (RIV), other tyrosine kinase inhibitors (TKI), hepatic arterial infusion chemotherapy (HAIC), and trans arterial chemoembolization (TACE). LEN-based combinations offered the highest survival benefits, suggesting a synergistic action in reducing tumor burden. While TACE based regimens offered the highest immediate response and control rate, these therapies were associated with a significantly higher risk of chemotherapy-associated adverse events. Combination therapies with LEN or RIV significantly reduced the risk of adverse events, implying a safer profile."

Combination therapy • Retrospective data • Review • Anemia • Hematological Disorders • Hepatocellular Cancer • Oncology • Solid Tumor

A real-world study on epidemiology, biomarker test results, clinical characteristics, and treatment patterns of unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma in China. (ASCO 2025) - "Oxaliplatin + tegafur was the most common 1L treatment, received by 3431/14,386 (23.8%) la/m Ga pts (median treatment duration: 2.9 mo [IQR: 1.4–5.6]) and 921/4335 (21.2%) la/m GEJa pts (2.8 mo [IQR: 1.4–5.4]). Treatment patterns suggest an ongoing need to improve the care of la/m Ga and GEJa in China."

Biomarker • Clinical • IO biomarker • Metastases • Real-world • Real-world evidence • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2 • PD-L1

Sequential hepatic artery infusion chemotherapy and transarterial chemoembolization combined with anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors and immune checkpoint inhibitors (quadruple therapy) as first-line therapy for advanced hepatocellular carcinoma: A single-center retrospective cohort study. (ASCO 2025) - "Enrolled patients were treated by sequential FOLFOX-HAIC and TACE combined with anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors (including apatinib in 4 cases, bevacizumab in 4 cases, donafenib in 2 cases, and lenvatinib in 28 cases) and immune checkpoint inhibitors (including PD-1 antibody in 34 cases and PD-L1 antibody in 4 cases)... Sequential hepatic artery infusion chemotherapy and transarterial chemoembolization combined with anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors and immune checkpoint inhibitors achieved encouraging outcomes with accepted adverse events in advanced HCC patients. These findings warrant further validation in a large randomized clinical trial."

Checkpoint inhibition • Metastases • Retrospective data • Hematological Disorders • Hepatocellular Cancer • Hepatology • Leukopenia • Oncology • Pain • Solid Tumor • Thrombocytopenia

Continuation of serplulimab-based therapy beyond first progression in advanced gastric/gastroesophageal junction (G/GEJ) cancer: Preliminary results from the SCAFIGC trial. (ASCO 2025) - P2 | "All patients received 6-8 cycles of serplulimab combined with XELOX (oxaliplatin and capecitabine), followed by maintenance serplulimab plus capecitabine until disease progression, intolerable toxicity, or death...These patients were randomized (2:1) to receive serplulimab combined with apatinib and paclitaxel or paclitaxel ± ramucirumab... Patients with advanced G/GEJ cancer demonstrate promising clinical efficacy and manageable safety after receiving first-line serplulimab combined with chemotherapy. Further follow-up is needed to assess the potential for long-term benefit and to evaluate the efficacy and safety of the stage II treatment."

Metastases • Gastric Cancer • Oncology • HER-2 • PD-L1

Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial. (ASCO 2025) - P3 | "The combination of camrelizumab, rivoceranib, and TACE as a perioperative treatment demonstrates both efficacy and tolerability in patients with resectable HCC. Preoperative neoadjuvant therapy has demonstrated promising pathological response. However, due to the short follow-up duration, further research is required to determine whether perioperative treatment can effectively reduce recurrence rates and improve long-term survival outcomes."

Clinical • Hepatitis B • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

Perioperative camrelizumab plus apatinib and gemcitabine-oxaliplatin in patients with borderline resectable biliary tract malignancies: A multicenter, single-arm, phase II trial. (ASCO 2025) - P2 | "Perioperative camrelizumab plus apatinib and GEMOX demonstrated high ORR and R0 resection rates in patients with borderline resectable biliary tract malignancies. Toxicities were manageable and consistent with the known safety profiles of these agents. These findings warrant further exploration of this regimen as a potentially effective multimodal treatment strategy."

Clinical • P2 data • Anemia • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gallbladder Cancer • Neutropenia • Oncology • Renal Disease • Thrombocytopenia

Neoadjuvant systemic chemotherapy combined with camrelizumab (CAM) and apatinib (APA) for BCLC stage A/B hepatocellular carcinoma (HCC) beyond Milan criteria: An interim analysis of a phase 2 trial. (ASCO 2025) - "The enrolled pts received CAM (200 mg, q3w), APA (250 mg, qd), and mFOLFOX7 (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2400 mg/m2 for 46 hours; q3w; up to 6 cycles). Neoadjuvant mFOLFOX7 combined with Camrelizumab and Apatinib is effective and tolerable in pts with BCLC stage A/B HCC beyond Milan criteria. Preoperative neoadjuvant therapy has reduced the rate of MVI. More data would be further analyzed and reported."

Clinical • P2 data • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Comparison of efficacy and safety of lenvatinib vs. apatinib in combination with hepatic arterial infusion chemotherapy and immune checkpoint inhibitors for unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective study. (ASCO 2025) - "Lenvatinib appears to be a better choice for combination therapy in uICC, demonstrating superior OS, PFS, and ORR compared to apatinib. However, apatinib may have a lower incidence of severe AEs. Further prospective studies with larger patient populations are required."

Checkpoint inhibition • Combination therapy • Retrospective data • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

STAR-01: A randomized phase III clinical trial comparing PD-1 combined with apatinib and SOX,PD-1 combined with SOX, versus SOX alone in patients with advanced gastric adenocarcinoma. (ASCO 2025) - P4 | "In conversion therapy for advanced gastric cancer, the combination of PD-1+SOX could improve ORR, pCR, R0 resection rate and survival expectation of patients compared with SOX alone. However, whether apatinib is introduced or not can not improve the ORR rate and survival of patients."

Clinical • Metastases • P3 data • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor • PD-1

Cryoablation combined with camrelizumab and apatinib in advanced hepatocellular carcinoma: A prospective, single-arm, phase II study. (ASCO 2025) - P2 | "Cryoablation combined with apatinib and camrelizumab as the first-line strategy for aHCC patients with PVTT and below up-to-7 criteria demonstratebeld a promising value by improving ORR and OS with acceptable side effects. Baseline characteristics of patients"

Clinical • Metastases • P2 data • Hepatitis B • Hepatocellular Cancer • Hepatology • Hypertension • Oncology • Renal Disease • Solid Tumor • Thrombosis